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Transgelin is a TGFβ-inducible gene that regulates
osteoblastic and adipogenic differentiation of human
skeletal stem cells through actin cytoskeleston
organization
M Elsafadi*,1,2, M Manikandan1, RA Dawud3,4, NM Alajez1, R Hamam1, M Alfayez1, M Kassem1,2, A Aldahmash1,2,5 and A Mahmood*,1
Regenerative medicine is a novel approach for treating conditions in which enhanced bone regeneration is required. We identified
transgelin (TAGLN), a transforming growth factor beta (TGFβ)-inducible gene, as an upregulated gene during in vitro osteoblastic
and adipocytic differentiation of human bone marrow-derived stromal (skeletal) stem cells (hMSC). siRNA-mediated gene silencing
of TAGLN impaired lineage differentiation into osteoblasts and adipocytes but enhanced cell proliferation. Additional functional
studies revealed that TAGLN deficiency impaired hMSC cell motility and in vitro transwell cell migration. On the other hand, TAGLN
overexpression reduced hMSC cell proliferation, but enhanced cell migration, osteoblastic and adipocytic differentiation, and
in vivo bone formation. In addition, deficiency or overexpression of TAGLN in hMSC was associated with significant changes in
cellular and nuclear morphology and cytoplasmic organelle composition as demonstrated by high content imaging and
transmission electron microscopy that revealed pronounced alterations in the distribution of the actin filament and changes in
cytoskeletal organization. Molecular signature of TAGLN-deficient hMSC showed that several genes and genetic pathways
associated with cell differentiation, including regulation of actin cytoskeleton and focal adhesion pathways, were downregulated.
Our data demonstrate that TAGLN has a role in generating committed progenitor cells from undifferentiated hMSC by regulating
cytoskeleton organization. Targeting TAGLN is a plausible approach to enrich for committed hMSC cells needed for regenerative
medicine application.
Cell Death and Disease (2016) 7, e2321; doi:10.1038/cddis.2016.196; published online 4 August 2016
Regenerative medicine through employing stem cell trans-
plantation is a novel approach for treating conditions in which
enhanced bone regeneration is required. A number of stem
cell types have been envisaged as candidates for use in
therapy. Human bone marrow-derived stromal (also known as
skeletal or mesenchymal) stem cells (hMSCs) is one of the
most promising candidates. Optimal use of hMSC in therapy
requires detailed understanding of molecular mechanisms of
lineage commitment and differentiation as well as identifying
regulatory factors that can be targeted for controlling hMSC
differentiation and functions.
Global hypothesis generating methods, for example, DNA
microarrays, proteomic analysis, and miRNA microarrays
have been employed by our group in order to identify factors
relevant to hMSC biology and functions and that exhibit sign-
ificant changes during lineage-specific differentiation.1–5 This
approach has led to the identification of several factors that
control osteoblast or adipocyte differentiation of hMSC.3 Using
transcriptomic profiling of differentiating hMSC, we identified
transgelin (TAGLN) as a highly upregulated gene in hMSC
during osteoblast and adipocyte differentiation.
TNGLN is a transforming growth factor beta (TGFβ)-
inducible gene6 that functions as an actin-crosslinking/gelling
protein of the calponin family. It is localized to the cytoskeleton
and is expressed by endothelial, smooth muscle cells,
fibroblasts as well as several immune cells.7 It has several
names: mouse p27, WS3-10, and SM22.8 It is transiently
expressed in heart and skeletal muscle cells during early
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mouse embryogenesis.9 It is known as one of the earliest
commitment markers of differentiated smooth muscle
cells,10–12 and has been suggested to regulate their contractile
functions. TAGLN-deficient mice were fertile and developed
normally;13 however, vascular smoothmuscle cells exhibited a
pronounced alterations in the distribution of the actin filament
and changes in cytoskeletal organization.14
The aim of this studywas thus to examine the novel biological
role for TAGLN in regulating hMSC lineage-specific differentia-
tion and functions. We employed a number of cellular and
molecular approaches including loss-of-function and gain-of-
function studies. Our data suggest that TAGLN is important for
differentiation progression of hMSC through regulation of
distribution of actin filaments and cytoskeletal organization.
Results
Activation of TGFβ1 signaling induces TAGLN expres-
sion and enhances hMSC differentiation. We have identi-
fied TAGLN as one out of 11 genes that were upregulated
during osteogenic differentiation and adipogenic differentia-
tion of hMSC as well as enriched in the hMSC clone 1 high
osteogenic cell (CL1) cell line, which is an hMSC cell line that
exhibits enhanced osteogenic and adipogenic differentiation
(Figure 1a). We chose TAGLN as its role in regulating hMSC
differentiation has not been investigated. Given the known
role of TGFβ signaling in regulating TAGLN expression, we
subsequently assessed the effect of TGFβ treatment on
TAGLN expression and hMSC differentiation. Adding TGFβ1
(10 ng/ml) to osteoblast induction medium enhanced osteo-
blast differentiation as evidenced by increased extracellular
mineralized matrix formation (Figures 1b and c) and expres-
sion of osteoblast lineage gene markers: RUNX2 (runt related
runt related transcription factor 2), ALPL (alkaline phospha-
tase, liver/bone/kidney) and osteocalcin (OC; Figure 1d).
Similarly, TGFβ1 enhanced adipocytic differentiation as evi-
denced by increased formation of mature lipid-filled adipocytes
(Figures 1e and f) and expression of adipocyte lineage gene
markers: PPARG2 (peroxisome proliferator activated receptor
gamma), LPL (lipoprotein lipase), and adiponectin (ADIPOQ;
Figure 1g). Adding TGFβ1 signaling inhibitor SB 431542 (SB;
10 μm) to the induction media abolished TGFβ1-stimulatory
effect (Figures 1b–g). As seen in Figure 1h, the enhanced
osteoblast and adipocyte differentiation by TGFβ1 treatment
was associated with increased expression of TAGLN. Dose–
response experiments revealed induction of TAGLN by TGFβ1
in a concentration range 0.1–20 ng/ml following 24 or 48 h
treatment (Figure 1i). The specificity of TGFβ1 induction of
TAGLN was confirmed by adding SB 431542 (10 μm) to the
culture media for variable time (2 h–72 h) that resulted in
inhibition of TAGLN expression already after 2 h treatment and
with a maximal effect observed after 24 h and it continued for
72 h (Figure 1j). We confirmed the induction of TAGLN by
TGFβ1 and inhibition by SB using western blot analysis
(Supplementary Figure S1A). To investigate whether the
TGFβ1-induced TAGLN expression is mediated by the SMAD2-
/3 pathway, we tested phosphorylation levels of SMAD2 and
found that TGFβ1 treatment increased phospho-SMAD2 levels
(Supplementary Figure S1B).
TAGLN-depleted cells exhibited impaired osteoblast and
adipocyte differentiation. As the enhanced osteoblastic and
adipocytic differentiation by TGFβ1 was associated with
increased TAGLN expression, we employed a loss-of-function
approach to assess the role of TAGLN in the differentiation
processes. Small interfering RNA (siRNA)-targeting TAGLN
downregulated TAGLN gene expression (Figure 2a) even in the
presence of TGFβ1 (10 ng/ml; Figure 2a). Western blot
analysis confirmed suppression of TAGLN expression at the
protein level (Supplementary Figure S1C).
As shown inFigure 2b, TAGLN-siRNAcells exhibited impaired
osteoblast differentiation demonstrated by significant reduction
in mineralized matrix formation in absence or presence of
TGFβ1 treatment (10 ng/ml; Figure 2b) that was confirmed by
alizarin red quantification (Figure 2c), and decreased expression
of osteoblastic genemarkers:RUNX2,ALPL,COL1A1 (collagen
type I alpha), COL1A2, periostin (POSTN), and DICKKOPF-
related protein 2 (DKK2; Figure 2d and Supplementary
Figure S1D). The following markers RUNX2, POSTN, and
DKK2 were upregulated in the presence of TGFβ1 and were
significantly decreased in TAGLN-siRNA cells (Supplementary
Figure S1D). Similarly, TAGLN-siRNA cells exhibited impaired
adipocytic differentiation shown by decreased number of lipid-
filled mature adipocytes quantified by Nile Red staining
(Figure 2e) and decreased expression of adipocytic gene
markers: PPARΥ2, LPL, AP2, and ADIPOQ (Figure 2f). The
effects of TAGLNdeficiencyon hMSCdifferentiationwere further
confirmed by establishing hMSC with a stable knockdown of
TAGLN using shRNA (TAGLN-shRNA), where similar results
were obtained (Supplementary Figure S2).
TAGLN overexpression exhibited enhanced osteoblast
and adipocyte differentiation of hMSC. We established a
TAGLN stably overexpressing hMSC-TERT (TAGLN-hMSC)
by lentiviral transduction. The overexpression of TAGLN was
confirmed by quantitative real-time polymerase chain reac-
tion (qRT-PCR; Figure 3a), western blot analysis (Figure 3b),
and immunocytochemical staining (Figure 3c). To examine
the in vivo differentiation capacity, TAGLN-hMSC cells were
mixed with hydroxyapatite–tricalcium phosphate (HA/TCP)
and implanted subcutaneously into non-obese diabetic/
severe combined immunodeficiency (NOD/SCID) mice.
Histological analysis of the implants revealed significant
increased formation of ectopic bone in TAGLN-hMSC, as
assessed by twofold increase in quantification of newly
formed bone of TAGLN-hMSC comparing with the control
(Figure 3d). Following differentiation induction, TAGLN-hMSC
exhibited enhanced differentiation to osteoblastic cells
evidenced by increased Alizarin Red S staining for formed
mineralized matrix and expression of osteogenic gene
markers (Figures 3e–g). In addition, adipocyte differentiation
was enhanced as shown by increased number of Nile Red-
positive mature adipocytes and significant upregulation of
adipocytic gene expression (Figures 3h–j).
TAGLN-overexpressing hFFs exhibited enhanced osteo-
blastic and adipocytic differentiation. To confirm that
TAGLN’s osteogenic and adipogenic induction potential is
not restricted to BM-derived hMSC, we sought to assess the
role of TAGLN-hFFs).4 The TAGLN-hFF cells showed
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upregulation of TAGLN messenger RNA (mRNA) compared
with control hFFs (Figure 4a), and increased protein
expression as shown by immunocytochemical staining
(Figure 4b) and western blot analysis (Figure 4c). TAGLN-
hFFs exhibited decreased in proliferation rate, enhanced cell
motility, and cell differentiation (Figures 4d–i).
TAGLN inhibited hMS cell proliferation. To study the
effects of TAGLN on hMSC on the overall changes in cell
number, we employed one standard assay that measured cell
viability, which is Alamar blue assay and a state-of-the-art
real-time monitoring cell number using real-time cell analysis
(RTCA, DP system). In addition, we applied growth curves
based on direct cell counting and expressed as cumulative
population doublings (PDs) over 18 days of culture, in which
TAGLN-shRNA exhibited higher PD rate compared
with control cells (Figure 5a). RTCA DP system and Alamar
blue assays showed increased proliferation in TAGLN-shRNA
(Figures 5b and c). On the other hand, TAGLN-hMSC
exhibited decreased cell viability (Figure 5d).
TAGLN enhanced hMSC migration. TAGLN has previously
been implicated in cell migration;6,15–19 however, the role of
TAGLN expression in hMSC migration has not been studied.
Figure 1 Activation of TGFβ1 signaling induces TAGLN expression and enhances hMSC differentiation. (a) Venn diagram depicting the overlap between the differentially
upregulated genes during osteogenic differentiation of hMSC, the upregulated genes during adipogenic differentiation of hMSC and the upregulated genes of CL1 versus CL2
cells. CL1 cells were differentiated into osteoblasts by osteogenic mixture for 7 days. (b) Mineralized matrix stained by Alizarin Red S (×20, magnification). (c) Quantification of
Alizarin Red S staining: control non-induced culture (NI), osteoblast-induced cultures (OS), with TGFβ1 (10 ng/ml) or SB 431542 (10 μm). (d) qRT-PCR performed for osteogenic
markers, including ALPL, RUNX2, and OSC. Cells were differentiated into adipocytes by adipogenic induction mixture for 7 days. (e) Oil red-O staining of mature lipid-filled
adipocytes (×20, magnification). (f) Quantification of Nile Red staining of mature lipid-filled adipocytes: non-induced controls (NI), adipocyte-induced (AD), with TGFβ1 (10 ng/ml),
or SB 431542 (10 μm). (g) qRT-PCR for adipogenic markers: LPL, aP2 (adipocyte protein 2), PPARG, and ADIPOQ. (h) qRT-PCR of gene expression of TAGLN gene following
osteogenic and adipogenic induction: D0 (non-induced), D1, D3, and D7 with and without TGFβ1 induction. D= day. (I) Time- (24 and 48 h) and dose- (TGFB1: Control, 0.1, 1, 2,
10, and 20 ng/ml) response induction of TAGLN gene expression following treatment with TGFB. (j) Time-response suppression of TAGLN gene expression in response to SB
431542 (SB). Expression of target gene was normalized to GAPDH. Data are shown as mean± S.D. of three independent experiments, *Po0.05; **Po0.01, ***Po0.005
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Thus, we studied the effects of TAGLN deficiency and
overexpression on hMSC cell migration in two independent
assays. In scratch assays, TAGLN-hMSC migrated faster and
tended to close the scratch defect compared with control
cells or TAGLN-shRNA (Figures 6a and b). We have also
conducted transwell migration assay using the RTCA DP
system that revealed impaired migration of TAGLN-shRNA
compared with control cells (Figure 6c).
TAGLN-shRNA cells exhibited cellular and nuclear mor-
phological changes. The observed effects of TAGLN on
hMSC cell migration prompted us to study its effects on cell
morphology and cytoskeleton. For this, we employed high
content imaging using Opretta of Phalloidin-fluorescein
isothiocyanate (FITC) staining for F-actin. As shown in
Figure 6, TAGLN-shRNA cells exhibited increased cell
roundness, percentage of rounded cells, index of nuclei
mean roundness, and nuclei width to length ratio, but reduced
cell area and nuclear area (Figure 6d). F-Actin staining
revealed decreased staining intensity in TAGLN-shRNA cells
(Figure 6e).
In addition, we employed transmission electron microscopic
examination of TAGLN-shRNA cells and TAGLN-hMSC
(Figure 7,Supplementary Figures S3–S6). In control cells,
we observed prominent actin filament organized as bundles/
aggregates and distributed in the whole cytoplasm and in
perinuclear locations. In addition, the cells contained surface-
branched microvilli. In contrast, TAGLN-shRNA contained
relatively fewer actin filaments, whereas TAGLN-hMSC
showed high content of actin filaments. Furthermore, rough
endoplasmic reticulum (rER) was dilated in TAGLN-hMSC,
suggesting increased protein synthesis activity. Interestingly,
cellular processes were observed extending from TAGLN-
hMSC that may enhance cellular motility. The ultrastructural
characteristics of the examined cells are summarized in
Supplementary Table C.
Gene expression profiling of TAGLN-depleted cells. In
order to determine the molecular mechanisms underlying
TAGLN functions in hMSC biology, we performed global gene
expression profiling in TAGLN-siRNA cells and control cells.
Hierarchical clustering revealed that control and TAGLN-
siRNA samples clustered separately (Figure 8a). We found
Figure 2 siRNA-mediated TAGLN suppression inhibits osteogenesis and adipogenesis. (a) Quantitative qRT-PCR for TAGLN gene expression 3 days post-TAGLN-siRNA, or
scramble-siRNA transfection. Data are presented as fold induction. All further controls represent scramble-transfected cells. (b) Alizarin Red S staining for mineralized matrix
formation. (c) Quantification of Alizarin Red staining: NI, OS, and TAGLN-siRNA cells cultured in osteoblast induction media in presence or absence of TGFβ1. (d) qRT-PCR of
gene expression of osteogenic markers (ALPL, RUNX2, COL1A1, and COL1A2): NI, OS, and TAGLN-siRNA cells cultured in osteoblast-induction media. (e) Cells were induced
using adipocyte induction mixture for 5 days and stained by Nile red for quantification of mature lipid-filled adipocytes: NI, AD, and adipocyte-induced cultures in presence of
TGFβ1 (AD+TGFβ1) in control cells or cells transfected with TAGLN-siRNA. (f) qRT-PCR was performed for adipogenic markers' gene expression: PPARG, LPL, AP2 (adipocyte
protein 2), and ADIPOQ: NI, AD, and adipocyte-induced cultures in presence of TGFβ1 (AD+TGFβ1). Expression of each target gene was normalized to GAPDH. Data are
presented as mean ± S.D. from three independent biological samples from at least two independent experiments. ** Po0.01, ***Po0.005
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that 6351 genes were upregulated and 3159 genes were
downregulated in TAGLN-siRNA cells compared with control
cells (fold change (FC)≥2.0, Po0.02, Supplementary Table F).
Among the significantly downregulated genes were integrin
family (ITGA4, ITGA10, and ITGB1BP1), TPM1, Fos,
SRF, and CSRP3 as well as mesodermal genes such as
twist family (TWIST1 and TWIST2), and MFH-1, FoxC2
(Figure 8b). In addition, osteoblast-associated genes such as
ALPL and BMP4 were downregulated (Figure 8b). In addition,
Venn diagram showed 60 common downregulated genes in
TAGLN-deficient cells during osteoblast and adipocyte
differentiation including NR1H3, CDF, IGF2, and IGFBP2,
which could potentially have a role in commitment of hMSC to
osteoblastic and adipocytic lineage (Figure 8c). As a
confirmation of the microarray data, qRT-PCR showed good
concordance between microarray and qRT-PCR for a
selected gene panel and are known to be involved in cell
differentiation and the TGFβ pathway (Figure 8d).
Pathway analysis of significantly regulated genes in
TAGLN-siRNA cells. TAGLN-siRNA cells exhibited down-
regulation in several intracellular signaling pathways
including pathways regulating actin cytoskeleton, focal
adhesions (FAs), endochondral ossification, adipogenesis,
TGFβ signaling, and MAPK cascade (Figure 8e,Supple-
mentary Figures S10–S13). Figure 8e shows a pie chart of
Figure 3 TAGLN overexpression induces osteogenesis and adipogenesis in hMSC. (a) All controls represent empty vector-transfected cells. qRT-PCR of TAGLN gene
expression in control (empty vector) hMSC and TAGLN-overexpressing line (TAGLN-hMSC). (b) Western blotting for TAGLN in TAGLN-hMSC (upper panel) and B-Actin (lower
panel). (c) TAGLN immunocytochemical staining in control hMSC and TAGLN-hMSC cells at magnification × 40 and × 60. Cells were differentiated into osteoblasts by osteogenic
or adipogenic induction mixture for 14 days. (d) hMSC and TAGLN-hMSC cells were implanted with HA/TCP subcutaneously into NOD/SCID mice. The histology of in vivo formed
bone was examined with H&E staining (original magnification × 200). High-resolution whole-slide digital scans of all histological sections were created with a ScanScope scanner
and bone formed was quantified. (e) Mineralized bone matrix formation in control hMSC (empty vector) cells and TAGLN-hMSC stained for Alizarin Red. (f) Quantification of
Alizarin Red staining in control hMSC and TAGLN-hMSC. (g) qRT-PCR for osteogenic markers: ALPL, OSC, COL1A1 (collagen type I), and OSP: NI, OS, and osteoblast-induced
TAGLN-hMSC (OS TAGLN-hMSC). (h) Both control (empty vector) hMSC, and TAGLN-hMSC were induced to adipocyte differentiation using adipocyte induction medium for
7 days. Mature lipid-filled adipocytes were stained by oil red. (i) Quantification of Nile Red staining for mature adipocytes: control (empty vector) hMSC, TAGLN-hMSC. (j) qRT-
PCR for adipogenic markers: ADIPOQ, LPL, AP2 (adipocyte protein 2), and PPARG in NI, AD, and adipo-induced TAGLN-hMSC line (AD TAGLN-hMSC). Data are shown as
mean±S.D. from at least two independent experiments, *Po0.05; ** Po0.01, ***Po0.005
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the top significantly regulated signaling pathways in
TAGLN-siRNA cells. Interestingly, 21 FA genes and 18 actin
cytoskeleton-regulating genes were downregulated in
TAGLN-siRNA cells including AKT1, AKT2, PFN1, ARPC5,
VIL2, and integrins (Supplementary Table D).
Gene expression profiling in TAGLN-siRNA during osteo-
blast differentiation. Transcriptomic profiling was con-
ducted on CL1 control and TAGLN-depleted cells on day 3
of osteogenic differentiation. As shown in Supplementary
Figure S7A, hierarchical clustering revealed clear separation
of the control and TAGLN-siRNA samples. A list of the
17 osteogenic genes that were downregulated in TAGLN-
siRNA cells is shown in Supplementary Figure S7B and
includes BMP4, COL12A1, CL8A1, FZD1, IGF2, and
SMAD6. Comparing the list of the downregulated genes in
TAGLN-siRNA cells and the upregulated genes in the CL1
control cells, in the presence of osteogenic induction medium,
identified 256 overlapped genes that are predicted to be
involved in osteogenic differentiation (Supplementary
Figure S7C). Furthermore, using significance analysis,
6004 up- and 2752 downregulated genes were identified in
TAGLN-depleted cells during osteogenesis (2.0 FC, Po0.02,
Supplementary Table F). Pathway analysis on the down-
regulated genes using GeneSpring GX revealed significant
changes in several pathways related to osteogenesis
including osteoblast signaling, osteopontin signaling,
TGFβ1 signaling, adipogenesis, endochondral ossification,
Figure 4 Effects of TAGLN overexpression on hFFs functions. (a) qRT-PCR of TAGLN gene expression in control (empty vector) TAGLN-hFFs. (b) Immunocytochemical
staining for TAGLN protein in control hFFs, and TAGLN-hFFs at magnifications × 40 and × 60. (c) Western blot of TAGLN (upper panel) and B-Actin (lower panel) in control hFFs
and TAGLN-hFFs. Cells were induced to differentiate into osteoblasts or adipocytes by either osteogenic or adipogenic mixture for 24 days. (d) Alamar blue staining for cell viability
in control hFFs and TAGLN-hFFs on day (D): 1D, 2D, 3D, and 4D. (e) Scratch assay where the motility of hFFs and TAGLN-hFFs cells was observed at different time intervals: 0,
24, 30, and 50 h. (f) Alizarin Red S staining for mineralized matrix formation. (g) Quantification of mineralized matrix formation in control hFFs cells and TAGLN-hFFs using Osteo-
Image Mineralization Assay. (h) Control hFFs and hFF-TAGLN were induced to adipocyte differentiation by incubation in adipocyte induction medium for 24 days and stained by oil
red for lipid-filled mature adipocytes. (i) Quantification of Nile red staining of mature adipocytes formed in control hFF cells and TAGLN-hFFs. Data are shown as mean±S.D. of
three independent experiments. **Po0.01, ***Po0.005
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and regulation of microtubule cytoskeleton (Supplementary
Figure S7D).
Gene expression profiling in TAGLN-depleted cells
during adipocytic differentiation. Global gene expression
profiling was conducted on parental and TAGLN-siRNA cells
on day 3 of adipogenic differentiation. As shown in
Supplementary Figure S8A, hierarchical clustering revealed
clear separation of the CL1 control cells and TAGLN-siRNA
cells. Using significance analysis, 2990 up- and 4717
downregulated genes were identified in TAGLN-depleted
cells during adipogenesis (2.0 FC, Po0.02, Supplementary
Table F). In addition, the adipogenic inhibition in TAGLN-
siRNA cells was associated with downregulation of adipo-
genic markers including FABP4, LPL, ADIRF, LIPE, APOL4,
APOL6, AOC3, and CEBPA (Supplementary Figure S8B).
Comparing the list of the downregulated genes in TAGL
N-siRNA cells and the upregulated genes in control cells, in
the presence of adipogenic induction medium, revealed 729
common genes, which are predicted to be involved in
adipogenic differentiation (Supplementary Figure S8C). Path-
way analysis revealed significant enrichment in several
pathways related to the TGFβ1 signaling pathway, adipogen-
esis, fatty-acid biosynthesis, integrin-mediated cell adhesion,
and cell differentiation (Supplementary Figure S8D).
Discussion
Identifying regulatory factors that have a role in hMSC
proliferation and differentiation is prerequisite for their optimal
use in regenerative medicine protocols. In the present study,
we unraveled novel roles for TAGLN in hMSC proliferation,
migration, and differentiation. TAGLN was observed to be
upregulated during hMSC lineage differentiation and in
Figure 5 TAGLN inhibits cells proliferation. (a) Short-term growth curve showing cumulative PD over 18-day culture of control CL1 (CNT) and TAGLN-deficient cells (TAGLN-
shRNA). (b) Alamar blue staining showing cell viability in control cells (CNT) and TAGLN-shRNA on days (D) 2, D3, and D4. (c) Proliferation assay using DIC device with the
RTCA DP system. CNTand TAGLN-shRNA. Cell proliferation was measured at 15-min intervals for 27 h (lower panel). Upper panel shows cell proliferation slope during the 27 h
observation period. (d) Alamar blue staining for control hMSC and TAGLN-overexpressing hMSC (TAGLN-hMSC) during 4 days of culture. Data are shown as mean± S.D. of at
least two independent experiments. **Po0.01, ***Po0.005
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response to TGFβ activation. TAGLN-mediated TGFβ-depen-
dent enhancement of lineage differentiation into osteoblasts
and adipocytes inhibited hMSC cell proliferation and
enhanced their migratory capacity. These effects are possibly
mediated through changes in actin distribution and cytoske-
leton dynamics.
We observed that TGFβ1 upregulated TAGLN expression in
hMSC, and these effectswere specific, as theywere abolished
by TGFβ-signaling inhibitor SB 431542. TAGLN expression
was associated with increased SMAD phosphorylation.
Previous studies have reported that TGFβ1 upregulated
TAGLN expression in a number of cell models, for example,
smooth muscle cells, epithelial cells, neural crest stem cells
Monc-1, and embryonic fibroblast cells (BALB 3T3).6,20,21
In addition, TGFβ1-induced TAGLN expression is mediated by
the SMAD2/3 signaling pathway.6,22 Thus, TGFβ-mediated
TAGLN expression represents a general phenomenon.
Interestingly, adding TGFβ1 to hMSC induction media
induced both osteogenic and adipogenic differentiation, and
these effects were dependent on TAGLN as they were
abolished in TAGLN-deficient hMSC. TGFβ1 exerts complex
effects on hMSCs. It has been demonstrated that it regulates
proliferation and differentiation of osteoprogenitor cells.23–26
We observed that TAGLN exerted opposing effects on
hMSC proliferation (inhibition) and differentiation (enhance-
ment). Similar phenomenon has been observed in rat
calvarial cultures where osteoblast differentiation coincided
with decreased cell proliferation.27 It is plausible that
Figure 6 TAGLN induces changes in cell morphology and enhances transwell cell migration. Scratch assay where a scratch is made in 50–70% confluent cells and cell
motility is observed at 0, 24, 30, and 50 h in (a) control CL1 (control) and TAGLN-deficient cells (TAGLN-shRNA), and (b) control hMSC and TAGLN-overexpressing hMSC
(TAGLN-hMSC). (c) Transwell migration assay using DIC device with the RTCA DP system. FBS was used as chemoattractant. The curves show the number of cell migrated up to
40 h (lower panel). Control empty vector cells (CNT) and TAGLN-shRNA cultured in presence of 1 or 10% FBS. The cell migration was measured at 15 min intervals for 45 h.
Upper panel shows the average cell migration slope during 24 h. (d) High content image analysis using Opretta of cell morphology in TAGLN-shRNA as compared with CNT. (e)
Immunocytochemical staining for F-Actin protein in CNTand TAGLN-shRNA. (f) High content image analysis of GFP intensity and the number of GFP-positive cells in CNTand
TAGLN-shRNA
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TAGLN-mediated effects are based on increasing the com-
mitted precursor pool, thus allowing more cells to differentiate
into osteoblasts and adipocytes. Taken together, we proposed
that the molecular changes mediated via TGFβ-induced
TAGLN defines the biological process of hMSCs, and their
osteogenic and adipogenic differentiation and proliferation
potential.
In our studies, TAGLN enhanced hMSCmigration. Similar to
our findings, TAGLN silencing inhibited TGFβ1-induced cell
migration in lung fibrosis model.6 Interestingly, it has been
hypothesized that TGFβ1 released from the bone matrix
during bone resorption phase of bone remodeling mediates
coupling of bone resorption to bone formation by inducing
migration of hMSC to the bone-formation sites.28,29 It is
plausible that the enhanced hMSC motility and migration is
achieved through upregulation of TAGLN andmay thus have a
role in recruiting progenitor cells to the bone-formation sites.
TAGLN overexpression or deficiency resulted in significant
changes in cell morphology, cytoskeleton, and functional
capacity for migration. It has been reported that TAGLN is
localized to cellular cytoskeleton and filamentous actin, which
are the principal components of the cytoskeleton,13,30–32 and
thus can actively contribute to regulation of cell shape and cell
polarity. The observed changes in cell morphology and
cytoskeleton may have a role in hMSC differentiation. It has
been reported that significant changes took place in the
cytoskeleton during lineage commitment and differentiation of
hMSC.33,34 During hMSCs' lineage commitment, the cells
undergo significant modifications in morphology and actin
cytoskeletal organization, and this participates in cell-fate
determination.33 In addition, during osteoblast differentiation,
hMSCs morphologically change from fibroblast-like cells to
cuboidal morphology, which is associated with changes in the
cytoskeleton.35 Similarly, during differentiation of hMSCs to
Figure 7 Transmission electron microscopy (TEM) analysis. Ultra-thin sections from resin embedded samples were ultrastructural analyzed using TEM. (a-c) Control empty
vector (CL1) cells with magnification x12 000, x15 000 and x50 000 respectively. (d-f) TAGLN deficient cells (TAGLN-shRNA) with magnification x12 000, x25 000 and x40 000
respectively. (g-i) Control empty vector hMSC (hMSC) cells with magnification x12 000, x25 000 and x40 000 respectively. (j-l) hMSC overexpressing TAGLN (TAGLN-hMSC)
cells with magnification x10 000, x25 000 and x40 000 respectively. AC, actin filaments; B, cell blebs; EV, endocytotic vacuole; G, Golgi bodies; IF, infolding of nuclear membranes;
M, mitochondria; N, nucleus; Nu, nucleolus; P, cell processes; PL, primary lysosome; rER, rough endoplasmic reticulum; SL, secondary lysosome; V, microvilli
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adipocytes, significant changes in cell morphology takes
place.36,37 Our data are in concordance with previous work
showing that TGFβ1 treatment suppresses MSC proliferation
and participates in cytoskeleton changes and thus hMSC
differentiation.38 Finally, osteoblast differentiation in response
to mechanical stimulation is associated with alteration in actin
cytoskeletal organization and is regulated by signals trans-
mitted through membrane-associated adhesion molecules.39
The molecular mechanisms linking changes of the cytoske-
leton and hMSC differentiation are under investigation. One of
the extensively studied mechanisms involves Rho GTPase/
Rho-associated Kinase, adhesion kinases, and extracellular
matrix components that regulate Actin Depolymerization
Factor (ADF) expression, for example, Destrin, Coflin1, and
Coflin2.40–42 A recent study from our group has demonstrated
that, during osteoblast differentiation of hMSCs, alteration in
ADF expression leads to changes in the ratio of G-actin
(monomer) and F-actin (polymerized), and inhibit actin
depolymerization.33
Treating bone marrow-derived hMSCs with TGFβ1 has
previously reported to regulate differentiation potential of
MSCs.43 On the basis of our study, we propose that the
mechanism by which the TGFβ1/TAGLN axis regulates hMSC
differentiation into osteoblasts and adipocytes is through
changes in the cell cytoskeleton. Given that TAGLN is an
actin-crosslinking or actin-gelling protein,9,44 our studies
demonstrate that the structure of actin cytoskeleton deter-
mines the transition from undifferentiated to committed
differentiating hMSC. It is also plausible that osteoblast/
adipocyte-differentiated phenotype requires a special actin
cytoskeleton structure, which is distinct from the cytoskeletal
structure of proliferating undifferentiated cells.
Figure 8 Gene expression profiling of TAGLN-depleted cells (TAGLN-siRNA). (a) Hierarchical clustering of control cells (control) and TAGLN-siRNA. Each row represents a
biological sample and each column represents a transcript. Expression level of each gene in a single sample is depicted according to the color scale. (b) List of differentiation-
associated genes that were downregulated in TAGLN-siRNA. (c) Venn diagram revealing overlap between the upregulated genes and the downregulated genes in TAGLN-siRNA
following osteogenic and adipogenic differentiation, The list of the 60 common genes shown in the Venn diagram. (d) qRT-PCR validation of selected genes *Po 005;
***Po 0001. (e) Pie chart illustrating the distribution of the top pathways enriched in the downregulated genes in TAGLN-siRNA identified during osteoblast differentiation. (f) A
working model illustrating the effect of TGFβ-induced TAGLN expression on hMSC migration, and osteoblastic and adipocytic differentiation by modulating actin cytoskeletal
organization and focal adhesion molecules and suggesting NRIH3, CDF, IGFBP2, and IGF2 genes as downstream targets
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Interestingly, our TEM studies have revealed that rER was
cystically dilated in TAGLN-hMSC, suggesting an increased
protein synthesis activity. It has been shown by TEM that
the ultrastructure of human bone marrow hMSCs is rich in
rER with dilated cisternae45 and that there is a reduction
in the abundance of rER following osteoblast differentiation.46
Palomäki et al.47 have shown the presence of dilated rER
in undifferentiated bone marrow hMSCs, whereas, after
osteoblast differentiation, narrow rERs with more extracellular
matrix were formed. Our data suggest that the presence of
cystically dilated rER, which is an indication of hyperactivity of
rER, is a prerequisite at the early stage of hMSC commitment
to cell differentiation when enhanced protein synthesis is
required, and this is accompanied with cytoskeletal changes,
which regulate ER dynamics and activity. It is known that
during mitosis the cisternal ER network changes its intracel-
lular localization, because of cytoskeleton changes, to the
peripheral membrane away from the mitotic spindle and
chromosomes in order to not interfere with the segregation of
chromosomes.48,49 This might explain the increased cell
proliferation in TAGLN-depleted cells, which constitute abun-
dant of long-stalk cisternal rER.
It has been shown that cytoskeletal and FA corporate to
influence the shape, mechanical properties and differentiation
of MSCs.50–52 FAs (cell–matrix adhesions) are large macro-
molecular assemblies through which mechanical force and
regulatory signals are transmitted between the extracellular
matrix and an interacting cell.53 FA molecules such as ATK1,
ATK2, and integrins (for example, ITGA10, ITGA4, and ITGB8)
have an essential role in directing MSCs to osteogenic
differentiation by changing the cytoskeleton that initiates extra-
cellular matrix-induced osteogenic differentiation.54–56 Con-
cordantly, AKT1, AKT2, PFN1, ARPC5, VIL2, and integrins
were significantly downregulated upon TAGLN depletion,
suggesting their implication in actin polymerization-mediated
MSC differentiation.
In summary, we proposed a model (Figure 8f) where TGFB
regulates TAGLN expression and this leads to enhanced MSC
cell migration and osteoblast and adipocyte differentiation
through modulating actin cytoskeletal organization and FA
molecules. A number of possible molecules, for example,
NRIH3, CDF, IGFBP2, and IGF2, are possibly implicated in
this process. Our study thus provides a novel molecular insight
into the role of the TGFβ intracellular signaling pathway in
bone and bone marrow adipose tissue formation. In order to
control the lineage fate of hMSCs, TAGLN is postulated as a
potential target for pharmacological intervention.
Materials and Methods
Cell culture. We have employed the hMSC-TERT cell line, which was created
from primary normal human MSC by overexpressing human telomerase reverse
transcriptase gene.1,4 The hMSC-TERT cells have been extensively characterized,
and they exhibit similar cellular and molecular phenotypes to primary MSC.4 For
ease, we will refer to this cell line as hMSC for the remaining part of the manuscript.
For the current experiments, we employed two subclones derived from hMSC called
CL1 and hMSC clone 2 low osteogenic cell (CL2) that exhibits enhanced and
reduced differentiation potential to osteoblasts and adipocytes, respectively. In
addition, hFFs have been used to extend our functional studies of TAGLN. The cells
were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with
D-glucose 4500 mg/l, 4 mM L-Glutamine and 110 mg/l Sodium Pyruvate, 10% fetal
bovine serum (FBS), 1 × penicillin–streptomycin (Pen–strep), and non-essential
amino acids (all purchased from Gibco-Invitrogen, Waltham, MA, USA).
siRNA-mediated transfection of hMSC. For transfection, CL1 cells in the
logarithmic growth phase were reversed-transfected with Silencer Select Pre-
designed TAGLN-siRNA (25 nM; Ambion, Carlsbad, CA, USA; ID: s13739 and Cat.
No. 4392420; Ambion, The RNA Company, USA) using Lipofectamine RNAiMAX
Reagent (Invitrogen, CA, USA) plus serum-free Opti-MEMI medium (Invitrogen)
under the conditions described by the manufacturer. On day 3 of transfection, the
cells were induced to osteogenic or adipogenic differentiation for an additional
1 week. Detailed information about siRNA reagents is described in Supplementary
Table E.
Establishing a stable TAGLN-deficient (TAGLN-shRNA) line. CL1
cells were seeded in 24-well plates for 1 day, followed by forward transfection by
50 µl serum-free Opti-MEMI medium (Invitrogen) mixed with 0.5 µl of Lipofectamine
2000 Reagent (Invitrogen). The cells were incubated for 5 min and 1 µg of TAGLN-
shRNA (GeneCopoeia, Inc., Rockville, MD, USA; Cat. No. HSH017877-2-CH1) was
mixed with 50 µl serum-free Opti-MEMI medium (Invitrogen) and incubated for
5 min. One hundred microliters of shRNA and lipofectamine mixture were added to
0.5 ml pen–strep-free DMEM per well. Transfection medium was changed next day
with Pen–Strep-free DMEM and cultured for 3 days. Puromycin (1.5 mg/ml) was
added when the cells reached confluence. A OmicsLink shRNA Expression vector
was used (Cat. No.: HSH017877-1-CH1, OriGene Technologies (Rockville, MD,
USA)) for knocking down TAGLN with Puromycin as selection marker and GFP as
reporter gene. Detailed information about shRNA reagents is described in
Supplementary Table E and Supplementary Figure S18.
Establishing TAGLN-hMSC line. Lentiviral transduction was employed to
create stable hMSC cell lines overexpressing TAGLN. Lentiviral transduction was
conducted as previously described.5 Lentifect lentiviral particles encoding human
TAGLN (LP-G0046-Lv213-200) or control lentiviral particles (LP-FLUC-LV105-0205)
were purchased from GeneCopoeia Inc. Briefly, hundred thousand cells were
seeded in DMEM in 24-well plate. Forty-eight hours later (~80 confluency), media
were removed and then 20 μl of lentiviral particles in 500 μl of DMEM+5% heat-
inactivated serum (Invitrogen) and 1% Pen–Strep supplemented with polybrene
(8 μg/ml; Sigma, St. Louis, MO, USA) were added to the cells. Seventy-two hours
later, media were removed and transduced cells were expanded in T25 and
selected using puromycin (1.5 mg/ml; Sigma).
In vitro osteoblast differentiation. Cells were grown in standard DMEM
growth medium in six-well plates at 0.3x106 cells/ml. When 70–80% confluence, the
cells were cultured in DMEM supplemented with osteoblast induction mixture
containing 10% FBS, 1% Pen–strep, 50 μg/ml L-ascorbic acid (Wako Chemicals,
Neuss, Germany), 10 mM β-glycerophosphate (Sigma), and 10 nM calcitriol (1α,25-
dihydroxy vitamin D3; Sigma), and 10 nM dexamethasone (Sigma). The media were
replaced three times per week.
In vitro adipocyte differentiation. Cells were grown in standard DMEM
growth medium in six-well plates at 0.3 × 106 cells/ml. At 90–100% confluence, cells
were cultured in DMEM supplemented with adipogenic induction mixture containing
10% FBS, 10% horse serum (Sigma), 1% Pen–strep, 100 nM dexamethasone,
0.45 mM isobutyl methyl xanthine57 (Sigma), 3 μg/ml insulin (Sigma), and 1 μM
Rosiglitazone58 (Novo Nordisk, Bagsvaerd, Denmark). The media were replaced
three times per week.
Cytochemical staining
Alizarin Red S staining for mineralized matrix: The cell layer was washed
with PBS, and then fixed with 4% paraformaldehyde for 15 min at room
temperature. After removing the fixative, the cell layer was rinsed in distilled water
and stained with the 2% Alizarin Red S Staining Kit (ScienceCell, Research
Laboratories, Cat. No. 0223) for 20–30 min at room temperature. Excess dye was
washed off with water. For quantifying the Alizarin Red S staining, the Alizarin Red
S dye was eluted in 800 μl of acetic acid incubated in each well for 30 min at room
temperature as described59 and measured in spectrophotometer (BioTek, Epoch) at
405 nm.
Osteo-image mineralization assay: The in vitro formed mineralized matrix
was quantified using the Osteo-Image Mineralization Assay Kit (Lonza, Walkersville,
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MD, USA, Cat. No. PA-1503). Culture media were removed and cells washed once
with PBS, and fixed with 70% cold ethanol for 20 min. Appropriate amount as
recommended by the manufacturer of diluted staining reagent was added, and
plates were incubated in dark for 30 min at room temperature. Cells were washed,
and staining quantitation was performed using fluorescent plate reader at 492/520
excitation emission wavelengths.
Oil red-O staining for lipid droplets: Mature adipocytes filled with cytoplasmic
lipid droplets were visualized by staining with Oil Red-O. After washing with PBS,
the cells were fixed in 4% formaldehyde for 10 min at room temperature, and then
rinsed once with 3% isopropanol and stained for 1 h at room temperature with
filtered Oil Red-O staining solution (prepared by dissolving 0.5 g Oil red-O powder
in 60% isopropanol). To quantify the mature adipocytes formed, Oil Red-O stain was
eluted by adding 100% isopropanol to each well and color intensity was measured
with spectrophotometer at 510 nm (Biotek Spectrophotometer, Epoch).
Nile red fluorescence determination and quantification of mature
adipocytes: Stock solution of Nile red (1 mg/ml) in DMSO was prepared and
stored at − 20 °C protected from light. Staining was performed on fixed cells with
4% paraformaldehyde (Sigma) for 15 min. Cultured undifferentiated and
differentiated cells were washed once with PBS. The dye was added directly to
the cells (5 μg/ml in PBS), and the cells were incubated for 10 min at RT.
Fluorescent signal was measured using SpectraMax/M5 fluorescence spectro-
photometer plate reader (Molecular Devices Co., Sunnyvale, CA, USA) using the
bottom well-scan mode where nine readings were taken per well using excitation
485 nm and emission 572 nm spectra.
Immunocytochemical staining. The cells were fixed in 4% paraformalde-
hyde (Sigma) for 15 min, and were permeabilized with 0.1% Triton X-100 (Sigma)
for 10 min. To block nonspecific binding, cells were treated with 3% bovine serum
albumin (Sigma) for 30 min, and then incubated with TAGLN antibody (Thermo-
Fisher Scientific, Rockford, IL, USA, CAT# PA5-29767) diluted in PBS (1:100) at 4 °
C overnight. After washing the cells with PBS, they were treated with secondary
antibody (Goat polyclonal to anti-mouse and anti-rabbit IgG, Abcam) and incubated
for 1 h at room temperature.
Cell proliferation assays
Cell number: Cell number was determined after 2 or 3 days of culture. The cells
were cultured in T25 tissue culture flask dish at cell density 0.5 × 106 cells (28 000
cells/cm2). At confluence, the cells were trypsinized and counted manually with
hemocytometer. The proliferation curve is shown as cell number at each passage
against number of days in culture.
Alamar blue cell viability assay: Cell viability was measured using Alamar
blue assay according to the manufacturer's recommendations (AbD Serotec,
Raleigh, NC, USA). In brief, to cultured cells in 96-well plates 10 μl of Alamar blue
substrate was added and the plates were incubated in the dark at 37 °C for 1 h.
Reading was subsequently taken using fluorescent mode (Ex 530 nm/Em 590 nm)
using BioTek Synergy II microplate reader (BioTek Inc., Winooski, VT, USA).
RTCA cell proliferation assay: The RTCA DP system was used to measure
the cell proliferation rate. Cells were cultured for 24 h in 1% FBS-DMEM, followed
by adding 100 µl 10% FBS-DMEM to each well. E-plate 16 (ACEA Biosciences Inc.,
San Diego, CA, USA, ID: 691315, China) was placed onto PTCA DP analyzer inside
the 37 oC incubator. After 1 h, the background measurements were performed in
RTCA SW. This is followed by adding 5000 cells in 100 µl 10% FBS-media per well
to each well, and CIM plates containing the cells were placed in the DP system
inside the incubator followed by measurements with 15 min intervals.
Scratch assay. This assay was conducted as previously described.44 Overall,
0.2 × 106/cells/dish were plated on 30-mm cell culture dish. At confluence, the cell
monolayer was scraped in a straight line to create a 'scratch' with a p10 pipet head.
The debris was removed and markings to be used as reference points close to the
scratch were created by tip marker, and the plates were placed under the phase-
contrast microscope. Images of the scratch were acquired, and then the plates were
placed in the tissue culture incubator. After incubation, the plates were examined
with a phase-contrast microscope, and the reference points were matched. The
previously acquired photographed regions were aligned and additional images were
acquired. To determine the rate of cell migration, lines were drawn along the edges
of the scratch and the percentage of migrated cells at each time point was
estimated.
RTCA cell migration assay. RTCA migration assay measures the effect of
perturbations in electrical impedance in a label-free real-time setting. Migration
assay was applied using DIC device with the RTCA DP system using FBS as a
positive chemoattractant control. After 24 h incubation in 1% FBS-DMEM, the
bottom chamber wells of the RTCA Cim-16 plate (ACEA Biosciences Inc., ID:
368179) were filled with 160 µl media (for each sample two wells were used, one
filled with 1% FBS-media as a control and the other filled with 10% FBS-media as
chemoattractant). The upper chamber was placed over the bottom one and filled
with 25–50 µl 1% FBS-media to cover the membrane surface. CIM plate was placed
on PTCA DP analyzer inside the 37 oC incubator for 1 h incubation to allow the CIM
membrane surface to reach the equilibrium with the media. After 1 h the
background measurement was performed in RTCA SW. Cells (40 000) in 100 µl 1%
FBS-media were added to each well of the top chamber. The CIM plates containing
the cells were placed in the DP system inside the incubator, followed by the
measurement with 15 min intervals.
Western blotting. Whole-cell lysates were prepared as previously described.
Soluble proteins were analyzed by immunoblotting with TAGLN antibody (Thermo-
Fisher Scientific, CAT# PA5-29767, diluted 1 : 50 00), total SMAD, P-SMAD2 (Cell
Signaling, Boston, MA, USA, Cat. No. 9523, diluted 1:500), and anti-β-ACTIN
(Sigma, A3854, diluted 1:10 000). Reactivity was detected with horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas,
TX, USA) and Clarity western ECL substrate (Bio-Rad, Hercules, CA, USA) for
chemiluminescence using C-Digit Blot Scanner (LI-COR).
High content imaging using Opretta. Cells were plated in 96-cell carrier
microtiter plates (Perkin Elmer) at 1500 cells/well in standard culture medium
supplemented with 10% FCS at 37 °C. After 24 h, the cells were fixed in 4%
paraformaldehyde for 10 min, washed with PBS and stained for F-actin with
Phalloidin-FITC (Sigma) and for nuclear staining with DAPI. Fluorescent images
were analyzed using the Operetta high content imaging system (Perkin Elmer,
Waltham, MA, USA) at a × 20 magnification. Different parameters of cytoskeletal
changes were measured by using Harmony High Content Imaging and Analysis
Software (Perkin Elmer).
Transmission electron microscopy. After trypsinization, the cells were
washed with PBS and the cell pellets were resuspended in 2.5% glutaraldehyde
fixative (Electron Microscopy Sciences, Hatfield, PA, USA, Cat. No. 16500) in 0.1 M
phosphate buffer (pH 7.2) and kept at 4 °C for 4 h. The cells were washed in 0.1 M
phosphate buffer (pH 7.2) and transferred to 1% osmium tetroxide (OsO4) in 0.1 M
phosphate buffer (pH 7.2). The cells were dehydrated in ascending grades of
ethanol (10, 30, 50, 70, 90, and 100%) for 15 min each. The cells were then
resuspended in acetone for 15 min and were aliquoted into BEEM embedding
capsules and infiltrated with an acetone: resin mixture. Polymerization of the resin
was accomplished in an oven at 70 °C for 12 h. Semi-thin sections (0.5 μm
thickness) were prepared and stained with 1% Toluidine Blue. Ultrathin sections
(70 nm thickness) were prepared and mounted on copper grids. Ultrathin sections
were first contrasted with uranyl acetate (saturated ethanol solution) for 30 min,
rinsed, contrasted with Reynold's lead citrate for 5 min, and finally rinsed with
distilled water. The contrasted ultrathin sections were examined and photographed
under a TEM (Jeol 1010, Jeol, Tokyo, Japan).60
In vivo subcutaneous implantation studies. All animal experimental
procedures were approved by the animal care and use committees of the University
of South Denmark. Cells were harvested via trypsinization, washed in PBS, and
resuspended in PBS. Approximately 5 × 105 cells were mixed with 40 mg of
hydroxyapatite–tricalcium phosphate ceramic powder per each implant (HA/TCP,
Zimmer Scandinavia, Albertslund, Denmark) and implanted subcutaneously into the
dorsal surface of 8-week-old female NOD/SCID mice (NOD/LtSz-Prkdcscid), as
described in more detail previously.61 Three mice were used with two implants in
each mouse. After 14 weeks, the implants were recovered, fixed in 4%
paraformaldehyde, decalcified using formic acid solution (0.4 M formic acid and
0.5 M sodium formate), and embedded in paraffin.
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Histologic analyses. Tissue blocks were sectioned at 4 mm. Immunohisto-
chemical staining was performed on implants using DAKO En Vision and
PowerVision according to the manufacturer’s instructions (DAKO, Glostrup,
Denmark). Human-specific staining was performed for human Vimentin. Briefly,
paraffin sections were incubated for 1 h at room temperature with primary
antibodies diluted in ChemMate (DAKO). Sections were washed subsequently in
Tris-buffered saline (TBS, 0.05 M, pH 7.4), incubated for 30 min with secondary anti-
mouse Ig/HR-conjugated polymers (K4001, En Vision., DAKO), and visualized with
3.30 diaminobenzidine tetrahydrochloride (DAB, S3000, DAKO) according to the
manufacturer’s instruction. Controls were performed without addition of primary
antibodies and processed under identical conditions.
Image analysis methodology. High-resolution whole-slide digital scans of
all histological sections were created with a ScanScope scanner (Aperio
Technologies Inc., Buffalo Grove, IL, USA). Five images were captured for each
section. The digital slide images were examined using the Aperio’s ImageScope
viewing software (Aperio Technologies Inc.). Random snapshots were taken from
each section with × 10 objective magnification. Each snapshot measured
1 809 171.65 μm2 (~1.8 mm2). The images were then subjected to image analysis
using the ImageJ software (National Institute of Health). Each image was color-
thresholded so as to select only the pink color of osteoid tissue (as stained with
hematoxylin and eosin) and measured its area percentage relative to the total area
of the image. The analysis output results were then exported to Excel sheets and
subjected to statistical analysis.
DNA microarray global gene expression profiling. Total RNA was
extracted using PureLink RNA Mini Isolation Kit (Ambion by Life Technologies, USA,
Cat. No.: 12183018A) as recommended by the manufacturer. One hundred and fifty
nanograms of total RNA were labeled and then hybridized to the Agilent Human
SurePrint G3 Human GE 8 × 60 k v16 microarray chip (Agilent Technologies, Santa
Clara, CA, USA). All microarray experiments were conducted at the Microarray Core
Facility (Stem Cell Unit, King Saud University College of Medicine). Normalization
and data analyses were conducted using the GeneSpring GX software (Agilent
Technologies). Pathway analysis was conducted using the Single Experiment
Pathway analysis feature in GeneSpring 12.0 (Agilent Technologies) as described in
(ref. 5). Twofold cutoff with Po0.02 was used.
Quantitative real-time PCR (qRT-PCR). Total RNA was extracted using
the PureLink Kit (Ambion by Life Technologies, Cat. No.: 12183018A) as
recommended by the manufacturer. Total RNA was quantified using Nanodrop
spectrophotometer (Nanodrop 2000, ThermoScientific). Complementary DNA
(cDNA) was synthesized from 1 μg of the RNA using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem (ABI), USA) using Labnet, Multigene
themocycler according to the manufacturer's instructions. Relative levels of mRNA
were determined from cDNA using real-time PCR (ABI-Real-Time PCR Detection
System) with Power SYBR Green PCR Kit (ABI, UK), or with TaqMan Universal
master Mix II, no UNG (ABI) according to the manufacturer's instructions. Following
normalization to the reference gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), quantification of gene expression was carried out using a comparative Ct
method where ΔCT is the difference between the CT values of the target and
reference gene. Primers employed are listed in Supplementary Tables A and B.
Statistical analysis. All of the results were presented as the mean and S.D. of
at least three independent experiments. Student’s t-test was used for testing
differences between groups. P-values o0.05 was considered statistically
significant.
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